
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. has demonstrated strong sales momentum, particularly with Baqsimi, which experienced approximately a 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, supported by strategic collaborations and seasonal demand. The company is projected to achieve a return to double-digit growth in 2026, following a flat year-over-year topline in 2025, indicating solid recovery potential. Additionally, Primatene Mist's robust performance signals further revenue growth opportunities, enhancing the optimistic outlook on Amphastar's market position and valuation relative to its peers.
Bears say
Amphastar Pharmaceuticals Inc. is facing significant challenges that are likely to negatively impact its financial outlook, particularly due to increased competition in key product segments such as iron sucrose and glucagon, which are expected to generate sales much lower than previously anticipated. Specifically, projected annual sales for iron sucrose have been reduced from an expected $60 million to around $20 million, while glucagon sales are expected to drop below $70 million starting in 2026 due to intensified market competition. Additionally, the anticipated return to double-digit top-line growth in 2026 has been tempered to a range of high-single digits to low-double digits, reflecting concerns about the company's growth pipeline.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares